Cargando…
Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer
Thymidine kinase 1 (TK1) is an intracellular enzyme involved in DNA-precursor synthesis. Increased serum TK1 levels are used as a biomarker in various malignancies. We combined serum TK1 with PSA and evaluated its capacity to predict overall survival (OS) in 175 men with prostate cancer (PCa), detec...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049218/ https://www.ncbi.nlm.nih.gov/pubmed/36982234 http://dx.doi.org/10.3390/ijms24065160 |
_version_ | 1785014401650130944 |
---|---|
author | Tribukait, Bernhard Lundgren, Per-Olof Kjellman, Anders Norming, Ulf Nyman, Claes R. Jagarlmundi, Kiran Gustafsson, Ove |
author_facet | Tribukait, Bernhard Lundgren, Per-Olof Kjellman, Anders Norming, Ulf Nyman, Claes R. Jagarlmundi, Kiran Gustafsson, Ove |
author_sort | Tribukait, Bernhard |
collection | PubMed |
description | Thymidine kinase 1 (TK1) is an intracellular enzyme involved in DNA-precursor synthesis. Increased serum TK1 levels are used as a biomarker in various malignancies. We combined serum TK1 with PSA and evaluated its capacity to predict overall survival (OS) in 175 men with prostate cancer (PCa), detected by screening in 1988–1989 (n = 52) and during follow-up (median 22.6 years) (n = 123). TK1 was measured in frozen serum, age was stratified into four groups, and dates of PCa diagnosis and dates of death were obtained from Swedish population-based registries. The median concentration of TK1 and PSA was 0.25 and 3.8 ng/ml. TK1 was an independent variable of OS. In the multivariate analysis, PSA was not statistically significant in combination with age whereas the significance remained for TK1 + PSA. Measured once, TK1 + PSA predicted a difference of up to 10 years (depending on patient subgroup) in OS at a median of 9 years before PCa diagnosis. The TK1 concentration in 193 controls without malignancies did not differ from that of the PCa patients, hence TK1 was likely not released from incidental PCa. Thus, TK1 in the blood circulation may indicate the release of TK1 from sources other than cancers, nonetheless associated with OS. |
format | Online Article Text |
id | pubmed-10049218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100492182023-03-29 Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer Tribukait, Bernhard Lundgren, Per-Olof Kjellman, Anders Norming, Ulf Nyman, Claes R. Jagarlmundi, Kiran Gustafsson, Ove Int J Mol Sci Article Thymidine kinase 1 (TK1) is an intracellular enzyme involved in DNA-precursor synthesis. Increased serum TK1 levels are used as a biomarker in various malignancies. We combined serum TK1 with PSA and evaluated its capacity to predict overall survival (OS) in 175 men with prostate cancer (PCa), detected by screening in 1988–1989 (n = 52) and during follow-up (median 22.6 years) (n = 123). TK1 was measured in frozen serum, age was stratified into four groups, and dates of PCa diagnosis and dates of death were obtained from Swedish population-based registries. The median concentration of TK1 and PSA was 0.25 and 3.8 ng/ml. TK1 was an independent variable of OS. In the multivariate analysis, PSA was not statistically significant in combination with age whereas the significance remained for TK1 + PSA. Measured once, TK1 + PSA predicted a difference of up to 10 years (depending on patient subgroup) in OS at a median of 9 years before PCa diagnosis. The TK1 concentration in 193 controls without malignancies did not differ from that of the PCa patients, hence TK1 was likely not released from incidental PCa. Thus, TK1 in the blood circulation may indicate the release of TK1 from sources other than cancers, nonetheless associated with OS. MDPI 2023-03-08 /pmc/articles/PMC10049218/ /pubmed/36982234 http://dx.doi.org/10.3390/ijms24065160 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tribukait, Bernhard Lundgren, Per-Olof Kjellman, Anders Norming, Ulf Nyman, Claes R. Jagarlmundi, Kiran Gustafsson, Ove Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer |
title | Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer |
title_full | Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer |
title_fullStr | Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer |
title_full_unstemmed | Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer |
title_short | Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer |
title_sort | prediction of overall survival by thymidine kinase 1 combined with prostate-specific antigen in men with prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049218/ https://www.ncbi.nlm.nih.gov/pubmed/36982234 http://dx.doi.org/10.3390/ijms24065160 |
work_keys_str_mv | AT tribukaitbernhard predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer AT lundgrenperolof predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer AT kjellmananders predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer AT normingulf predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer AT nymanclaesr predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer AT jagarlmundikiran predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer AT gustafssonove predictionofoverallsurvivalbythymidinekinase1combinedwithprostatespecificantigeninmenwithprostatecancer |